These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 9586667)

  • 21. Biomarker profile and genetic abnormalities in lobular carcinoma in situ.
    Mohsin SK; O'Connell P; Allred DC; Libby AL
    Breast Cancer Res Treat; 2005 Apr; 90(3):249-56. PubMed ID: 15830138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.
    Fujii H; Szumel R; Marsh C; Zhou W; Gabrielson E
    Cancer Res; 1996 Nov; 56(22):5260-5. PubMed ID: 8912866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allelic loss of chromosomal arm 8p in breast cancer progression.
    Anbazhagan R; Fujii H; Gabrielson E
    Am J Pathol; 1998 Mar; 152(3):815-9. PubMed ID: 9502423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast.
    Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N
    Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of heterozygosity in ductal carcinoma in situ of the breast.
    Stratton MR; Collins N; Lakhani SR; Sloane JP
    J Pathol; 1995 Feb; 175(2):195-201. PubMed ID: 7738715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetic studies of early breast cancer evolution.
    O'Connell P; Pekkel V; Fuqua S; Osborne CK; Allred DC
    Breast Cancer Res Treat; 1994; 32(1):5-12. PubMed ID: 7819586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic pathways in the evolution of breast ductal carcinoma in situ.
    Farabegoli F; Champeme MH; Bieche I; Santini D; Ceccarelli C; Derenzini M; Lidereau R
    J Pathol; 2002 Mar; 196(3):280-6. PubMed ID: 11857490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.
    Maitra A; Wistuba II; Washington C; Virmani AK; Ashfaq R; Milchgrub S; Gazdar AF; Minna JD
    Am J Pathol; 2001 Jul; 159(1):119-30. PubMed ID: 11438460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity at chromosome 6q in preinvasive and early invasive breast carcinomas.
    Chappell SA; Walsh T; Walker RA; Shaw JA
    Br J Cancer; 1997; 75(9):1324-9. PubMed ID: 9155053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer.
    Euhus DM; Maitra A; Wistuba II; Alberts A; Albores-Saavedra J; Gazdar AF
    J Surg Res; 1999 May; 83(1):13-8. PubMed ID: 10210636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer.
    Zhuang Z; Merino MJ; Chuaqui R; Liotta LA; Emmert-Buck MR
    Cancer Res; 1995 Feb; 55(3):467-71. PubMed ID: 7834608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.
    Zikan M; Bohm J; Pavlista D; Cibula D
    Clin Transl Oncol; 2011 Sep; 13(9):652-5. PubMed ID: 21865136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of heterozygosity and microsatellite instability in epithelial hyperplasia of the breast.
    Kaneko M; Arihiro K; Takeshima Y; Fujii S; Inai K
    J Exp Ther Oncol; 2002; 2(1):9-18. PubMed ID: 12415615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic mutations and expression of p53 in non-invasive breast lesions.
    Mao X; Fan C; Wei J; Yao F; Jin F
    Mol Med Rep; 2010; 3(6):929-34. PubMed ID: 21472335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation at chromosome 11q23 in human non-familial breast cancer: a microdissection microsatellite analysis.
    Koreth J; Bethwaite PB; McGee JO
    J Pathol; 1995 May; 176(1):11-8. PubMed ID: 7616353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of heterozygosity at chromosome 9p in ductal carcinoma in situ and invasive carcinoma of the breast.
    Marsh KL; Varley JM
    Br J Cancer; 1998 May; 77(9):1439-47. PubMed ID: 9652759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS.
    Visser LL; Elshof LE; Van de Vijver K; Groen EJ; Almekinders MM; Sanders J; Bierman C; Peters D; Hofland I; Broeks A; van Leeuwen FE; Rutgers EJT; Schmidt MK; Schaapveld M; Lips EH; Wesseling J
    Am J Surg Pathol; 2019 Nov; 43(11):1574-1582. PubMed ID: 31206365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.